Ripretinib Patent Expiration
Ripretinib is Used for treating gastrointestinal stromal tumors in patients who have progressed through multiple lines of treatment, including tyrosine kinase inhibitors like imatinib. It was first introduced by Deciphera Pharmaceuticals Llc
Ripretinib Patents
Given below is the list of patents protecting Ripretinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Qinlock | US11779572 | Methods of treating gastrointestinal stromal tumors | Oct 06, 2042 | Deciphera Pharms |
| Qinlock | US11969414 | Methods of treating gastrointestinal stromal tumors | Feb 08, 2041 | Deciphera Pharms |
| Qinlock | US11185535 | Amorphous kinase inhibitor formulations and methods of use thereof | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11395818 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11576903 | Amorphous kinase inhibitor formulations and methods of use thereof | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11612591 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11793795 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11801237 | Amorphous kinase inhibitor formulations and methods of use thereof | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11844788 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11850240 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11850241 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11896585 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11903933 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11911370 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11918564 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US11969415 | (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US12023328 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US12064422 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US12213967 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US12213968 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US12226406 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Dec 30, 2040 | Deciphera Pharms |
| Qinlock | US10966966 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US11266635 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US11344536 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US11426390 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US11433056 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US11529336 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US11534432 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US11576904 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US11813251 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US12023325 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US12023326 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US12023327 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US12059410 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US12059411 | Methods of treating gastrointestinal stromal tumors | Aug 12, 2040 | Deciphera Pharms |
| Qinlock | US8461179 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | May 15, 2034 | Deciphera Pharms |
| Qinlock | US8940756 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | Jun 07, 2032 | Deciphera Pharms |
| Qinlock | USRE48731 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | Jun 07, 2032 | Deciphera Pharms |
| Qinlock | US8188113 | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | Jul 27, 2030 | Deciphera Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ripretinib's patents.
Latest Legal Activities on Ripretinib's Patents
Given below is the list recent legal activities going on the following patents of Ripretinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11903933 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11896585 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11844788 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11813251 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11850240 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11850241 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11793795 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11779572 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11801237 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11911370 |
Ripretinib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List